Synchron Raises $200M Series D for BCI Expansion and Next-Gen Development
Synchron, a neurotechnology company based in New York, announced it has raised $200 million in a Series D funding round to advance commercialization of its brain-computer interface system, Stentrode. With this investment, the company’s total funding now stands at $345 million.
Funding and Investors
The new financing round was led by Double Point Ventures and included participation from existing investors such as ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS. New investors joining the round were Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT.
Commercial Plans and Research Expansion
Synchron plans to use the proceeds to accelerate pivotal clinical trials and scale preparation for the Stentrode system launch. The company is also expanding its team of engineers, neuroscientists, and clinical operators to enhance next-generation BCI capabilities.
Technological Development
A portion of the funding will support ongoing work in the Cognitive AI division in New York, where researchers are training models to interpret brain data and decode human thought in real time. In parallel, Synchron has opened a new engineering hub in San Diego to develop advanced brain interface technology.
About Stentrode
Stentrode is a minimally invasive implant that detects motor intention from within brain blood vessels. Synchron states it is the only BCI using endovascular access to capture brain signals directly from the motor cortex.
The device is implanted via the jugular vein and sits on the surface of the motor cortex, enabling communication directly from the brain to external systems.
Author Summary
Synchron’s $200M Series D funding positions it to scale its BCI system Stentrode, speed up clinical trials, and push forward next-generation neurotechnology innovations.